Search filters

Filters

Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 152
  • 17
  • 402
  • 1246
  • 593
  • 29
  • 49
  • 3
  • 1172
  • 1247
  • 6
  • 4
  • 1249

Found 1253 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 UPCC 15217: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

UPCC 15217: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

18 years - 99 years
All genders
Phase 3
The main purpose of this study is to find out if the study drug ARQ 087 is safe and effective to use in patients with intrahepatic cholangiocarcinoma.
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
 Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol

Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) Protocol

40 years - 64 years
All genders
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's …
 A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

All genders
Phase 1
A5369 is a phase I/IIa, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and efficacy of p24CE/full-length Gag DNA, as a therapeutic vaccine in HIV-1 infected persons. The study targets to enroll 40 participants. All participants are well-suppressed on ART, current CD4 T cell counts greater than 500 cells/mm3, …
 AN UN-BLINDED  INTRA-PATIENT COMPARISON OF TRANSBRONCHIAL FORCEPS BIOPSY AND CRYOBIOPSY FOR PERIPHERAL PULMONARY LESIONS

AN UN-BLINDED INTRA-PATIENT COMPARISON OF TRANSBRONCHIAL FORCEPS BIOPSY AND CRYOBIOPSY FOR PERIPHERAL PULMONARY LESIONS

All genders
Peripheral lung nodules seen on CT scans require a diagnostic evaluation as they commonly represent small, treatable lung cancers. In order to diagnose these lung lesions, bronchoscopy with small lung biopsies is often the preferred first step. However, this procedure is not always successful as not all biopsies obtain enough …
 Network Control TMS fMRI

Network Control TMS fMRI

18 years - 28 years
All genders
The University of Pennsylvania seeks young adults ages 18-28 for a research study. The purpose of this study is to use different types of MRI scans to find individualized TMS (transcranial magnetic stimulation) targets and compare how the brain responds. We are also interested in using TMS during a working …

Changes in the lymphatic system on MR Lymphangiography (MRL) in patients with congestive heart failure (CHF).

All genders
Observational study of adults with congestive heart failure and normal healthy participants using Magnetic Resonance Imaging (MRI) to compare changes in the lymphatic system (thin tubes and lymph nodes that run throughout the body).

A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in patients with cardiogenic managed with VA ECMO (REVERSE)

All genders
Veno-arterial (VA) extra-corporeal membrane oxygenation (ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock. VA ECMO has a number of effects on the circulation including (i) perfusing end-organs, (ii) ventricular unloading, and (iii) improved coronary perfusion. It is a bridge …
201 - 210 of 1253